ClinicalTrials.gg
CompletedNCT00596648Updated Jan 13, 2026Results posted

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

A Phase 1/2 interventional study of XL184 and erlotinib in Carcinoma, Non-Small-Cell Lung, sponsored by Exelixis. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Exelixis · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, none of them phase 3. cabozantinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 16
92 · median 39
Started
2008
the only one that year
Phase 1/2
2 of 16
none open now
Registered
1st of 16
by date
Lead sponsor
3 of 16
Exelixis

Among the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 1/2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study consisted of a Phase 1 dose escalation/dose de-escalation portion to determine a safe and tolerable combination dose(s) of cabozantinib and erlotinib, and a Phase 2 Simon optimal 2-stage design portion with randomized assignment of subjects in an equal ratio to determine the objective response rate (ORR) of cabozantinib with or without erlotinib in subjects with non-small cell lung cancer (NSCLC) who have progressed after responding to treatment with erlotinib. The doses of cabozantinib used in this study were based on the salt weight, not the freebase weight.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Lung Cancer
  • Non-Small-Cell Lung Cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria-Phase 1:

  • Subjects had confirmed NSCLC and currently have Stage IIIb or IV NSCLC
  • Subjects had failed treatment with erlotinib at 150 mg qd
  • Subjects had tolerated erlotinib at the dose of the cohort in which they were enrolled (or at a higher dose) for at least 6 weeks (or for the duration of treatment if disease progression had occurred during treatment with erlotinib for less than 6 weeks)
  • The subject was at least 18 years old
  • The subject had an performance status of \< 2
  • The subject had organ and marrow function as follows: - ≥ 1500/mm3, ≥ 100,000/mm3, ≥ 9 g/dL, ≤ 1.5 times the , serum creatinine ≤ 1.5 mg/dL or if serum creatinine > 1.5 mg/dL calculated ≥ 60 mL/min, (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal, amylase and lipase \< 1.5 times the upper limit of normal
  • Sexually active subjects had to agree to use medically accepted methods of during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)
  • Female subjects of had to have a negative pregnancy test at enrollment. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression
  • The subject had no other diagnosis of (unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed ≥ 2 years previously, and currently with no evidence of disease)

Exclusion Criteria-Phase 1:

  • The subject had received anti-cancer treatment (eg, chemotherapy, radiotherapy, cytokines, or hormones) within 4 weeks with exception of erlotinib (6 weeks for nitrosoureas or mitomycin C) before the first dose of study drug
  • The subject had not recovered to National Cancer Institute (NCI) (CTCAE) v3.0 Grade ≤1 from adverse events (AEs) due to antineoplastic agents, drugs, or other medications that were administered prior to study enrollment
  • The subject had symptomatic or uncontrolled requiring current treatment, including and anticonvulsants
  • The subject had a history of clinically significant hematemesis or a recent history of hemoptysis of > 0.5 teaspoon of red blood or other signs indicative of pulmonary hemorrhage
  • The subject had the presence of cavitation, endobronchial lesion or a lesion abutting a major blood vessel
  • The subject had serious intercurrent illness, such as uncontrolled hypertension (sustained blood pressure [BP] readings of > 140 mmHg systolic or > 90 mmHg diastolic not controlled with anti-hypertensive medication), unhealed wounds from recent surgery or clinically significant cardiac arrhythmias or a recent history of significant disease such as either symptomatic congestive heart failure or unstable angina pectoris within 3 months or myocardial infarction within 6 months before the first dose of study drug
  • The subject was pregnant or breastfeeding
  • The subject had an active infection requiring systemic treatment
  • The subject had an allergy or to components of either the cabozantinib or erlotinib formulations
  • The subject was incapable of understanding and complying with the protocol or unable to provide

Inclusion Criteria-Phase 2

  • Subjects had pathologically confirmed NSCLC and currently have Stage IIIb or IV NSCLC
  • Subjects had: Documented radiological PD, following a prior response, per investigator assessment, to monotherapy with erlotinib, OR; Documented radiological PD, per investigator assessment, following stable disease of at least 6 months on monotherapy with erlotinib
  • Subjects who had received subsequent anti-cancer therapy after having progressed on erlotinib (as defined above) also had to have documented radiological PD per investigator assessment to their most recent anti-cancer therapy. If the most recent anti-cancer therapy was erlotinib after having previously progressed on erlotinib (as defined above) the subject also had to have documented radiological PD per investigator assessment to their most recent course of erlotinib
  • Subjects had to have tolerated erlotinib at the maximal dose that would be administered in Phase 2 (or at a higher dose) for a minimum of 6 weeks
  • Subjects had per
  • Subjects had to have 15 unstained consecutive slides of archival or fresh tumor tissue (from one tumor block, frozen tumor tissue, or a paraffin block) identified and designated for shipment to the sponsor if permitted by local regulations (including IRB [Institutional Review Board] policies). The eligibility of subjects with \< 15 unstained slides of available was discussed with the sponsor
  • The subject was at least 18 years old
  • The subject had an ECOG performance status of \< 1
  • The subject had organ and marrow function as follows: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, bilirubin ≤ 1.5 times the upper limit of normal, serum creatinine ≤ 1.5 mg/dL or if serum creatinine > 1.5 mg/dL calculated creatinine clearance ≥ 60 mL/min, ALT and AST ≤ 2.5 times the upper limit of normal, amylase and lipase \< 1.5 times the upper limit of normal
  • Sexually active subjects had to agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)
  • Female subjects of childbearing potential had to have a negative pregnancy test at enrollment. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression
  • The subject had no other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed ≥ 2 years previously, and currently with no evidence of disease)

Exclusion Criteria-Phase 2

  • The subject had received: Small molecule inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2)/ kinase insert domain receptor (KDR) at anytime, OR; An investigational anti-cancer agent within 4 weeks of the first dose of study drug, OR; Investigational small molecule inhibitors of EGFR at any time, OR; A small molecule inhibitor of epidermal growth factor (EGF)/EGFR at any time (with the exception of erlotinib and gefitinib), OR; Anti-cancer therapy, including radiation therapy, within 4 weeks of the first dose of study drug (with the exception of gefitinib and erlotinib), OR; Prior therapy with a c-Met inhibitor. Recent (within 3 months) radiation therapy to the thoracic cavity including brachytherapy, unless radiation therapy targeted only bone
  • The subject had not recovered to NCI CTCAE v3.0 Grade ≤1 from clinically significant AEs due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study enrollment
  • The subject had symptomatic or uncontrolled brain metastases requiring current treatment, including steroids and anticonvulsants
  • The subject had experienced clinically significant hematemesis or hemoptysis of > 0.5 teaspoon of red blood within 3 months before the first dose of study treatment, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
  • The subject had cavitating pulmonary lesion(s), known endobronchial disease or a pulmonary lesion abutting or encasing a major blood vessel
  • The subject had serious intercurrent illness, such as uncontrolled hypertension (sustained BP readings of > 140 mmHg systolic or > 90 mmHg diastolic not controlled with anti hypertensive medication), unhealed wounds from recent surgery or clinically significant cardiac arrhythmias or a recent history of significant disease such as either symptomatic congestive heart failure or unstable angina pectoris within the past 3 months, myocardial infarction, stroke, or within the past 6 months
  • The subject was pregnant or breastfeeding
  • The subject had a clinically significant active infection requiring systemic treatment
  • The subject had an allergy or hypersensitivity to components of either the cabozantinib or erlotinib formulations
  • The subject was incapable of understanding and complying with the protocol or unable to provide informed consent
  • The subject had a history of idiopathic pulmonary fibrosis or interstitial lung disease (ILD)
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Phase 1 Arm

    Escalating doses of XL184 + erlotinib

    Drug: XL184 · Drug: erlotinib

  • Experimental
    Phase 2 Arm 1

    XL184 + erlotinib (dose determined from Phase 1 portion of study)

    Drug: XL184 · Drug: erlotinib

  • Experimental
    Phase 2 Arm 2

    XL184 administered as a single agent

    Drug: XL184

Interventions

  • DrugXL184

    Capsules administered orally daily

  • Tablets administered orally daily.

06

What researchers measure

Primary outcomes

  1. Phase 1: Duration of Exposure of Cabozantinib With Erlotinib

    Treatment duration was defined as the number of days from the first dose to the last dose (measured in weeks), including any days of treatment interruption that occurred before the last dose of study drug.

    Time frame: From initial dose up to 160 weeks

  2. Phase 2: Objective Response Rate (ORR)

    Objective Response Rate is defined as the number of participants for whom the best overall response is complete (CR) or partial response (PR) confirmed by repeat assessments no less than four weeks after the criteria for the initial response were first met.

    Time frame: From initial dose up to 72 weeks

Secondary outcomes

  1. Phase 2: Duration of Response (DOR) in Participants With a CR or PR

    DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause.

    Time frame: From initial dose up to 72 weeks

  2. Phase 2: Progression-Free Survival (PFS)

    Progression-free survival is defined as the time from first dose of cabozantinib to disease progression per protocol-defined criteria or death due to any cause, whichever occurs first.

    Time frame: From initial dose up to 72 weeks

07

Results

Posted Jan 13, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase 1-Cohort 1Phase 1-Cohort 2APhase 1-Cohort 2BPhase 1-Cohort 3APhase 1-Cohort 4APhase 2-cabozantinibPhase 2-Cabozantinib + Erlotinib
Started3151715141513
Completed3141715141513
Not completed0100000

Outcome measures

PrimaryPhase 1: Duration of Exposure of Cabozantinib With Erlotinib

Treatment duration was defined as the number of days from the first dose to the last dose (measured in weeks), including any days of treatment interruption that occurred before the last dose of study drug.

Time frame:
From initial dose up to 160 weeks
Reported as:
Median · Weeks
Phase 1: Duration of Exposure of Cabozantinib With Erlotinib
WeeksPhase 1 - Cohort 1Phase 1 - Cohort 2APhase 1 - Cohort 2BPhase 1 - Cohort 3APhase 1 - Cohort 4A
Cabozantinib (XL184)4.43 (3.0 to 7.1)8.14 (2.1 to 143.6)8.00 (0.4 to 156.7)17.00 (6.1 to 80.3)20.07 (4.9 to 57.0)
Erlotinib6.57 (5.0 to 9.0)10.29 (4.1 to 146.3)10.00 (2.4 to 158.7)22.00 (8.9 to 84.3)22.07 (6.9 to 54.7)
PrimaryPhase 2: Objective Response Rate (ORR)

Objective Response Rate is defined as the number of participants for whom the best overall response is complete (CR) or partial response (PR) confirmed by repeat assessments no less than four weeks after the criteria for the initial response were first met.

Time frame:
From initial dose up to 72 weeks
Reported as:
Count of participants · Participants
Phase 2: Objective Response Rate (ORR)
ParticipantsPhase 2 - ARM 1, Cabozantinib ALONEPhase 2 - ARM 2, Cabozantinib + Erlotinib
Phase 2: Objective Response Rate (ORR)10
SecondaryPhase 2: Duration of Response (DOR) in Participants With a CR or PR

DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause.

Time frame:
From initial dose up to 72 weeks
Reported as:
Median · Weeks
Phase 2: Duration of Response (DOR) in Participants With a CR or PR
WeeksPhase 2 - ARM 1, Cabozantinib ALONEPhase 2 - ARM 2, Cabozantinib + Erlotinib
Phase 2: Duration of Response (DOR) in Participants With a CR or PRNA (NA to NA)—
SecondaryPhase 2: Progression-Free Survival (PFS)

Progression-free survival is defined as the time from first dose of cabozantinib to disease progression per protocol-defined criteria or death due to any cause, whichever occurs first.

Time frame:
From initial dose up to 72 weeks
Reported as:
Median · months
Phase 2: Progression-Free Survival (PFS)
monthsPhase 2 - ARM 1, Cabozantinib ALONEPhase 2 - ARM 2, Cabozantinib + Erlotinib
Phase 2: Progression-Free Survival (PFS)1.91 (1.64 to 7.06)3.94 (1.54 to 7.26)

Adverse events

Collected over From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 - Cohort 1—1/3 (33.3%)3/3 (100%)
Phase 1 - Cohort 2A—7/15 (46.7%)15/15 (100%)
Phase 1 - Cohort 2B—8/17 (47.1%)17/17 (100%)
Phase 1 - Cohort 3A—8/15 (53.3%)15/15 (100%)
Phase 1 - Cohort 4A—7/14 (50%)14/14 (100%)
Phase 2 - ARM 1, Cabozantinib ALONE—5/15 (33.3%)15/15 (100%)
Phase 2 - ARM 2, Cabozantinib + Erlotinib—11/13 (84.6%)12/13 (92.3%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventPhase 1 - Cohort 1Phase 1 - Cohort 2APhase 1 - Cohort 2BPhase 1 - Cohort 3APhase 1 - Cohort 4APhase 2 - ARM 1, Cabozantinib ALONEPhase 2 - ARM 2, Cabozantinib + Erlotinib
DEHYDRATIONMetabolism and nutrition disorders1/30/152/170/151/140/153/13
DIARRHOEAGastrointestinal disorders0/31/151/172/150/140/152/13
ABDOMINAL PAINGastrointestinal disorders0/30/150/170/152/140/150/13
PNEUMONIAInfections and infestations0/30/151/172/152/141/151/13
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/31/150/171/152/142/151/13
VOMITINGGastrointestinal disorders0/30/151/172/150/140/151/13
BACK PAINMusculoskeletal and connective tissue disorders0/30/152/171/150/140/150/13
NEUTROPENIABlood and lymphatic system disorders0/30/150/170/151/140/151/13
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/30/150/170/150/140/151/13
LARGE INTESTINE PERFORATIONGastrointestinal disorders0/30/150/170/150/140/151/13
Most frequent other events
Showing 10 of 284
Most frequent other events
EventPhase 1 - Cohort 1Phase 1 - Cohort 2APhase 1 - Cohort 2BPhase 1 - Cohort 3APhase 1 - Cohort 4APhase 2 - ARM 1, Cabozantinib ALONEPhase 2 - ARM 2, Cabozantinib + Erlotinib
DIARRHOEAGastrointestinal disorders3/314/1513/1713/1513/149/1510/13
FATIGUEGeneral disorders3/39/159/1710/1510/1413/1510/13
ALANINE AMINOTRANSFERASE INCREASEDInvestigations3/31/151/173/151/141/151/13
NAUSEAGastrointestinal disorders2/38/158/1712/159/149/157/13
DECREASED APPETITEMetabolism and nutrition disorders2/37/1511/1710/1511/148/155/13
THROMBOCYTOPENIABlood and lymphatic system disorders2/31/150/171/152/140/150/13
HYPOMAGNESAEMIAMetabolism and nutrition disorders2/34/152/176/155/142/154/13
DRY SKINSkin and subcutaneous tissue disorders2/34/151/171/154/146/151/13
RASHSkin and subcutaneous tissue disorders0/39/157/176/154/143/154/13
DYSGEUSIANervous system disorders0/33/154/178/156/143/153/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1-Cohort 1Phase 1-Cohort 2APhase 1-Cohort 2BPhase 1-Cohort 3APhase 1-Cohort 4APhase 2-cabozantinibPhase 2-cabozantinib + ErlotinibTotal
<=18 years00000000
Between 18 and 65 years281212712760
>=65 years175373632
Age, Continuous
Age, Continuous(years)Phase 1-Cohort 1Phase 1-Cohort 2APhase 1-Cohort 2BPhase 1-Cohort 3APhase 1-Cohort 4APhase 2-cabozantinibPhase 2-cabozantinib + ErlotinibTotal
Median56.1 (50 to 79)61.6 (30 to 77)61.4 (37 to 88)57 (35 to 74)64.5 (46 to 85)54.7 (36 to 74)64.8 (44 to 78)59.8 (30 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1-Cohort 1Phase 1-Cohort 2APhase 1-Cohort 2BPhase 1-Cohort 3APhase 1-Cohort 4APhase 2-cabozantinibPhase 2-cabozantinib + ErlotinibTotal
Female391310912763
Male064553629
08

Study locations

13 sites
  • Katmai Oncology Group
    Anchorage, Alaska 99508, United States
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
  • University of California, Davis
    Sacramento, California 95817, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Georgetown University/Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20007, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Park Nicollet Institute
    Saint Louis Park, Minnesota 55416, United States
  • Summit Medical Group
    Berkeley Heights, New Jersey 07922, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • University of Washington/ Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2008 to primary completion in Aug 2012, 53 months.

Results were first posted in Jan 2026, 13 years 5 months after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 53 months is close to that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2008
First posted
Jan 17, 2008
StartActual
Feb 12, 2008
Primary completionActual
Aug 2, 2012
CompletionActual
Aug 2, 2012
Results first posted
Jan 13, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00596648
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jan 17, 2008
Start date
Feb 12, 2008
Primary completion
Aug 2, 2012
Completion
Aug 2, 2012
Results posted
Jan 13, 2026
Last update
Jan 13, 2026

Study contacts

Medical Director
study director · Exelixis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion